What 2025 could bring for psychedelic use in healthcare

The article explores the anticipated developments in psychedelic medicine for 2025 following the FDA’s rejection of Lykos’ MDMA-based therapy in 2024. Industry players now aim to recalibrate clinical trials to address FDA concerns and generate reliable data. Thought leaders like Certara’s Dr. Fran Brown highlighted why companies developing psychedelic medicines should focus on learning from Lykos’s missteps.